Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Inclusion Criteria:

* Locally advanced or metastatic breast cancer
* Any estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (Her2neu) status as long as the patient will receive nab-paclitaxel alone
* First or second line chemotherapy treatment for metastatic disease
* Karnofsky performance status (KPS) \>= 70%
* Resolution of grade \>= 2 toxicity from prior therapy (other than alopecia)
* Peripheral neuropathy =\< grade 1
* Absolute neutrophil count \>= 1,500/mm\^3
* Platelets \>= 100,000 cells/mm\^3
* Hemoglobin (Hb) \>= 9.0 g/dl
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x institutional upper limit of normal
* Alkaline phosphatase =\< 2.5 x upper limit of normal unless bone metastasis are present in the absence of liver metastases
* Bilirubin =\< 1.5 mg/dl
* Creatinine clearance (calculated or 24 hour) \>= 30 ml/min
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients may not be receiving any other investigational agents
* Untreated central nervous system (CNS) metastases or symptomatic CNS metastases requiring escalating doses of corticosteroids
* Known history of allergic reactions to paclitaxel
* Presence of any serious or uncontrolled infection
* Receipt of a taxane for adjuvant therapy or metastatic disease in the last 12 months